 NEW YORK, Nov. 16, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, announced today the appointment of Kyung Nam-Wortman as Cellectis Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman, who will be based in Cellectis New York office, is also joining the Companys executive committee. 